Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Britain Courts Anthropic Amid US Defense Department Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple Turns 50: From Garage Startup to AI Crossroads 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
PHOENIX, Dec. 08, 2016 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today issued the following statement regarding the Department of Justice / U.S. Attorney’s Office / District of Massachusetts press release:
The charges against individuals discussed in the DOJ press release relate to previously disclosed investigations. Insys continues to cooperate with all relevant authorities in its ongoing investigations and is committed to complying with laws and regulations that govern our products and business practices. Insys will not provide additional information or comments at this time on this matter.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients.
Investor Contact: Lisa M. Wilson Email: [email protected]
